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Objectives: We used reflectance and fluorescence spectroscopy to noninvasively and quantitatively distinguish benign
from dysplastic/malignant oral lesions. We designed diagnostic algorithms to account for differences in the spectral prop-
erties among anatomic sites (gingiva, buccal mucosa, etc).
Mettiods: In vivo reflectance and fluorescence spectra were collected from 71 patients with oral lesions. The tissue was
then biopsied and the specimen evaluated by histopathology. Quantitative parameters related to tissue morphology and
biochemistry were extracted from the spectra. Diagnostic algorithms specific for combinations of sites with similar spec-
tral properties were developed.
Resutts: Discrimination of benign from dysplastic/malignant lesions was most successful when algorithms were de-
signed for individual sites (area under the receiver operator characteristic curve [ROC-AUC], 0.75 for the lateral surface
of the tongue) and was least accurate when all sites were combined (ROC-AUC, 0.60). The combination of sites with
similar spectral properties (floor of mouth and lateral surface of the tongue) yielded an ROC-AUC of 0.71.
Conctusions: Accurate spectroscopic detection of oral disease must account for spectral variations among anatomic sites.
Anatomy-based algorithms for single sites or combinations of sites demonstrated good diagnostic performance in distin-
guishing benign lesions from dysplastic/malignant lesions and consistently performed better than algorithms developed
for all sites combined.
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INTRODUCTION
Currently, definitive detection and diagnosis of
oral cancer requires biopsy followed by histopatho-
logic assessment of the excised tissue.' However,
there are several shortcomings to this scheme. First,
only a limited number of biopsy specimens can be
taken because of the invasiveness of the procedure.
On the basis of his or her experience, the physician
selects the area of the lesion most likely to show sig-
nificant disease as the biopsy site. The absence or
presence of disease in this specimen is assumed to
be representative of the extent of disease in the sus-
picious lesion as a whole, and this finding often de-
termines whether treatment is indicated.^ Given the
subjective nature of this process, regions of disease
can be missed. Significant underdiagnosis has been
noted with biopsy, particularly when the lesion is
nonhomogeneous or only a single biopsy specimen
is obtained.2'3 Second, the accuracy of pathological
classification is limited by significant interobserver
and intraobserver variability, largely due to the qual-
itative nature of the markers used for assessment."*"^
Spectroscopy may provide an objective and non-
invasive tool for disease diagnosis. Promising find-
ings have been reported for identifying oral lesions
by using reflectance and fluorescence spectrosco-
py 7-13 -phe majority of these studies have focused
on distinguishing healthy mucosa from visible le-
sions (either a group consisting of dysplastic and
malignant lesions ["dysplastic/malignant"] or ma-
lignant lesions).^-^-'^ "'^  However, this separation has
no clinical relevance, because these categories are
easily distinguished by visual inspection. In some
cases, benign lesions are grouped with healthy mu-
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cosa samples .^ '^ '^  Most studies combine data from
several anatomic sites (eg, gingiva, buccal mueosa)
in each category in generating diagnostic algorithms
based on differences in the spectral properties (spec-
tral contrast).7'io^n.i3,i4,i8,2i j^ j s approach may not
be ideal, because numerous studies have shown sig-
nificant differences in the spectral properties be-
tween various anatomic sites, even for healthy oral
mucosa.'''^ '^ ^" '^* We refer to the spectral contrast
produced by variations in histologie characteristics
from site to site as anatomic spectral contrast. The
presence of keratin on some sites (particularly the
gingiva and hard palate) produces marked anatomic
spectral contrast between these sites and nonkerati-
nized sites.^ '^ ^^ A recent study of clinically normal
mueosa in healthy volunteers (HVs) by our group
demonstrated considerable anatomic spectral con-
trast even among nonkeratinized sites .^ ^ The results
of our investigation suggested that spectral diagnos-
tic algorithms must be site-specific to ensure accu-
rate disease diagnosis. We use the term anatomy-
based algorithms to refer to algorithms that meet
this condition, in that they are developed from and
applied to a specific site or group of sites. Because
most studies combine several sites, the reported di-
agnostic accuracies may be confounded by anatom-
ic spectral contrast and therefore unreliable.
The distinction of benign lesions from dysplastic/
malignant lesions is not possible by visual inspec-
tion alone and has considerable clinical significance,
yet few spectroscopy studies focus on this separa-
tion .2'•2^ "^ *' Anatomic spectral contrast can also in-
fluence the diagnostic results for this separation if it
is not taken into account. In a study by de Veld et al,^ ^
for most analysis methods, values of less than 0.70
were obtained for the area under the receiver oper-
ator characteristic (ROC) curve (ROC-AUC) when
data from U anatomic sites were combined. Us-
ing fluorescence spectroscopy, van Staveren et al"
combined all sites and achieved a sensitivity of 31 %
and a specificity of 67%. Greater success has been
achieved in distinguishing lesions when the analy-
sis was limited to a single site or a specific group of
sites. Wang et aP^ performed a fluorescence study
of patients with lesions located only on the buccal
mueosa. They obtained a sensitivity of 81% and a
specificity of 96% for distinguishing benign lesions
from dysplastic/malignant lesions. Mallia et aF'
successfully developed diagnostic algorithms to dis-
criminate various oral lesions by using fluorescence
spectroscopy, but only after excluding lesions of the
vermilion border of the lip and of the dorsal and lat-
eral surfaces of the tongue. They suggested that a
separate spectral database is needed for these 3 sites.
In another study by Mallia et al,^ ^ reflectance spec-
troscopy was used to develop algorithms for all sites
combined and for the buccal mueosa (ie, an anato-
my-based algorithm). The sensitivities and specific-
ities obtained for algorithms specific to the buecal
mueosa were consistently higher for the discrimina-
tion of benign lesions from dysplastic lesions and
dysplastic lesions from malignant lesions. Müller et
al^ developed a diagnostie algorithm to distinguish
benign lesions from dysplastic/malignant lesions
specifically for keratinized sites, and they obtained
a higher sensitivity and specificity than when kera-
tinized and nonkeratinized sites were combined. Al-
though diagnostic algorithms for single sites or lim-
ited groups of sites have been investigated, a sys-
tematic approach for developing spectral algorithms
for multiple sites has not been developed.
The goal of the present study was to develop a
strategy for designing anatomy-based algorithms for
multiple anatomic sites. Although the spectral prop-
erties of different anatomic sites may vary consider-
ably, certain subsets may be similar enough in their
spectral properties such that they can be combined.
Furthermore, in many settings, developing a single
diagnostic algorithm for spectrally similar sites may
be more practical and less time-consuming than de-
veloping a diagnostic algorithm for each individual
site. Anatomy-based spectral diagnostic algorithms
are developed for 2 applications: \) distinguishing
visibly healthy mueosa from visible lesions, and 2)
distinguishing benign lesions from c|ysplastic/ma-
lignant lesions. The distinction of clinically normal
(healthy) mueosa from clinically abnormal mueosa
(lesions) has been the focus of most of the previous
studies in the oral cavity. We address the question of
whether anatomic spectral contrast affects the diag-
nostic accuracy of this separation. The second ap-
plication is the primary objective of this work, since
lesions demonstrating disease (dysplasia or malig-
nancy) require intervention.
From the tissue spectra, we extract parameters re-
lated to the morphological and biochemical proper-
ties. To account for anatomic spectral contrast, we
first study healthy mueosa from several anatomie
sites to characterize the similarities and differenc-
es in their spectroscopy parameters. We then ap-
ply these findings by developing common diagnos-
tic algorithms for combinations of sites that share a
high degree of spectral similarity. To evaluate the
benefit of anatomy-based algorithms, we compared
the performance of algorithms developed for these
specific combinations of sites to those developed
for all anatomic sites combined and to those for a
single anatomic site. We also examine the trends in
the spectroscopy parameters on the basis of disease
category.
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PATIENTS AND METHODS
Patients. Patients were recruited from the Depart-
ment of Otolaryngology-Head and Neck Surgery at
Boston Medical Center. The experimental protocol
for in vivo data collection was approved by the In-
stitutional Review Board of Boston Medical Center
and the Committee on the Use of Humans as Ex-
perimental Suhjects at the Massachusetts Institute of
Technology. Suhjects enrolled in the study included
patients undergoing hiopsy for clinically suspicious
lesions, as well as patients undergoing surgical re-
section of known dysplastic or malignant lesions.
Pregnant women and individuals under the age of
18 years were excluded from the study. Written in-
formed consent was obtained from all suhjeets to in-
dicate their willingness to participate. Spectral data
were collected from tissues with visible abnormali-
ties identified hy the clinician. The elinical appear-
ance of the lesions (eg, leukoplakia, erythroplakia)
was recorded. After collecting the spectral data, the
physician scored the exact area from which the data
were acquired using the hlade of a small punch hi-
opsy instrument (1.5 or 2 mm in diameter). The tis-
sue sample was subsequently removed using a larg-
er punch biopsy instrument (3.5 mm diameter) and
sent for histopathologie evaluation. In some eases, a
scalpel hiopsy was performed because of the lesion
architecture or location. Spectral data were collected
from multiple tissue samples in a patient when the
physician selected multiple areas of the lesion for
hiopsy, or when several hiopsies were performed of
a lesion to he resected. The histopathologie assess-
ment was performed hy 3 pathologists. Specimens
were classified as henign, dysplastic, malignant, or
indefinite for dysplasia. The consensus diagnosis
(agreement between at least 2 of the 3 pathologists)
was considered the final diagnosis. An additional set
of 710 spectra previously collected from 79 HVs at
9 anatomic sites was also analyzed, as described be-
low.25 Tissue samples from HVs were assumed to
represent healthy mueosa and were not hiopsied.
Data Collection. Reflectance and fluorescence
spectra were collected from patients using the Fast
Excitation Emission Matrix (FastEEM), an investi-
gational instrument developed hy our lahoratory that
has been previously described.^' A 1.3-mm-diame-
ter optical fiber probe was used to deliver the exci-
tation light and collect the light emitted from the tis-
sue. The optical fiher prohe was disinfected with Ci-
dex OPA (Advanced Sterilization Products, Irvine,
California) according to the manufacturer's specifi-
cations, and placed in contact with the tissue during
data collection. No exogenous contrast agents were
applied to the tissue. The data collection procedures
have heen further described elsewhere.^^ Data were
collected and analyzed from the following anatom-
ie sites: hueeal mueosa (BM), dorsal surface of the
tongue (DT), floor of the mouth (FM), gingiva (GI),
hard palate (HP), lateral surface ofthe tongue (LT),
retromolar trigone (RT), soft palate (SP), and ventral
surface ofthe tongue (VT).
Model-Based Analysis. We employed physical
models to extract morphological and biochemical
parameters from the tissue reflectance and fluores-
cence spectra. Details of the models are presented
in other reports.25.32,33 -pj^ g inputs to the reflectance
model are the reduced scattering coefficient, |as'(À.),
and the absorption coefficient, \\&(k). By modeling
the wavelength dependence of \i&', we extract 3 pa-
rameters: A, B, and C. The A parameter is a sealing
parameter proportional to the density of scatterers.
The B parameter reflects the size of the scattering
particles.3^* The C parameter represents the magni-
tude of scattering by small seatterers.
The ahsorption coefficient was modeled as the
sum ofthe eontrihutions from 2 ahsorbers, hemoglo-
hin (Hb) and ß-earotene (ßC). Hemoglohin absorp-
tion, |Ji»^*(X), was modeled with use of a correction
for the effeet of vessel packaging, whieh provides
the effective blood vessel radius as an additional fit-
ting parameter.25 By modeling the absorption, we
extracted the following 4 parameters: the concentra-
tion of Hb (eHb), the oxygen saturation (a), the ef-
fective vessel radius, and the concentration of ßC
(eßC). Henee, from the reflectance spectra we ex-
tracted 7 parameters in all: 3 scattering parameters
(A, B, C) and 4 ahsorption parameters.
We applied a physical model to the measured
fluorescence spectra in order to remove distortions
introduced by scattering and absorption and obtain
what we call the intrinsie fluoreseenee.33,35 j ^ or-
der to apply the findings of a study of the spectral
properties of healthy mueosa hy MeGee et aP^ to
the present study, data were analyzed at the same
2 excitation wavelengths (308 nm and 340 nm). At
308-nm excitation, the spectra were fit with a linear
combination of tryptophan (308 nm). Coll (308 nm),
and NADH (308 nm). The number in parentheses
represents the excitation wavelength. Coll refers to
collagen, and NADH refers to the reduced form of
nieotinamide adenine dinueleotide. At 340 nm exci-
tation, the spectra were fit with a linear combination
of NADH (340 nm), Coll401 (340 nm), and Coll427
(340 nm). Coll40] (340 nm) and Coll427 (340 nm)
are attributed to 2 distinct collagen components.^^
We obtained a total of 6 fluorescence parameters.
Overall, a total of 13 speetroseopy parameters were
used to characterize the degree of spectral similar-
ity between various sites and to construct diagnostic
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TABLE 1. TOTAL NUMBER OF SPECTRA MEASURED
AT EACH ANATOMIC SITE IN PATIENTS AND
PATHOLOGICAL CLASSIFICATION
TABLE 2. SIMILARITY SCORES FOR EACH PAIR OF
ANATOMIC SITES
Site Malignant Dysplastic Benign Total
Buccal mucosa (BM) 2 0 11 13
Dorsal surface of 0 0 4 4
tongue (DT)
Floor of mouth (FM) 2 11 3 16
Gingiva (GI) 0 1 0 1
Hard palate (HP) 1 1 2 4
Lateral surface of 4 9 12 25
tongue (LT)
Retromolar trigone (RT) 0 1 3 4
Soft palate (SP) 4 0 5 9
Ventral surface of 1 3 7 11
tongue (VT) .
Total 14 26 47 87
algorithms.
Identifying Spectrally Similar Anatomic Sites. We
compared the spectroscopy parameters extracted
from each of the 9 sites in the HV data to identify
anatomic sites that shared similar spectral proper-
ties and could be combined. The interquartile range
exclusion criteria were applied to the data to re-
move outliers (eg, from probe slippage, tissue move-
ment) .^ ^ For each spectroscopy parameter, a multi-
ple comparison test was performed to compare each
pair of sites and identify those that had statistically
different distributions. The Tukey-Kramer correc-
tion was applied to compensate for multiple com-
parisons. For each pair of anatomic sites, we calcu-
lated a "similarity score," the total number of spec-
troscopy parameters for which the distributions for
the 2 sites were not statistically different. Perfect
correspondence between the spectroscopy parame-
ter distributions for a pair of sites would be indicat-
ed by a similarity score of 13 (total number of spec-
troscopy parameters). We considered pairs of sites
with a similarity score of at least 10 to be spectrally
similar sites.
Spectral Diagnostic Algorithm Development. The
diagnostic performance of anatomy-based algo-
rithms developed for spectrally similar sites or in-
dividual sites was compared to that of algorithms
designed for all sites combined. Logistic regression
was used to develop the diagnostic algorithms. The
log-likelihood ratio test was used to identify the
spectroscopy parameters with the greatest diagnostic
potential for the distinction of healthy mucosa from
lesions and of benign lesions from dysplastic/ma-
lignant lesions .^ ^ The discriminatory power of each
algorithm was evaluated by leave-one-out cross-val-
idation and by calculating the ROC-AUC, sensitiv-
ity, and specificity. The sensitivities and specifici-
Site DT Œ HP
BM
DT
FM
GI
HP
LT
RT
SP
1
6
1
II
10
7
9
7
4
6
5
3
12
2
0
ties quoted in the subsequent analysis were selected
based on the Youden index, the point on the ROC
curve with the maximum vertical distance from the
45° line.38
The fewest parameters necessary to achieve the
maximum ROC-AUC for a comparison were re-
tained. To prevent overtraining, we limited the max-
imum number of spectroscopy parameters used in
the model to nl5, where n is the number of training
samples in the category with the fewest samples. To
further ensure the reliable assessment of the diag-
nostic algorithms, we only analyzed categories in
which there were at least 10 samples.
RESULTS
General Description of Data Set. A total of 71
patients were recruited for this study. The average
age (±SD) of the patients was 56+14 years. Of the
101 spectra collected from patients, 12 spectra from
7 patients were excluded because of an error noted
during data collection, a broken probe, or the poor
quality of the biopsy specimen, or because the pa-
thology results were unavailable. Two samples, one
of which was a lymphoma and another of which was
classified as ihdefinite for dysplasia, were also ex-
cluded. Thus, a total of 87 spectra collected from 64
patients were included in the final analysis (Table
1). The abbreviations for the 9 sites are also shown
in Table 1. The average age (±SD) of the 64 patients
was 56 ± 15 years. Data collected from HVs on the
BM, DT, FM, GI, HP, LT, RT, SP, and VT were used
in the subsequent analysis. These groups consisted
of 100,124,112,58,54,112,33,43, and 74 spectra,
respectively (not shown in Table 1).
Identification of Spectrally Similar Sites. The
set of 710 spectra collected from 9 anatomic sites
in HVs was used to calculate similarity scores for
each pair of sites and to identify which specific pairs
could be combined. There were pronounced differ-
ences in the spectral properties amcng the various
anatomic sites (Table 2). For 75% of the compari-
sons, the similarity score was 7 or less. We identi-
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TABLE 3.
Similarity
Score
10
12
II
DESCRIPTION OF SPECTRALLY SIMILAR
ANATOMIC SITES
Spectrally Similar
Sites
BM and SP
FM and VT
GI and HP
Dysplastic/
Malignant
6
17
3
Benign
16
10
2
TABLE 4. ROC-AUC VALUES FOR DISCRIMINATION
OF HEALTHY MUCOSA FROM LESIONS
fied sites with a high degree of similarity on the ba-
sis of a similarity score of at least 10. The following
3 pairs of sites met this criterion: 1) BM and SP, 2)
FM and VT, and 3) GI and HP. We refer to pairs of
sites with high similarity scores as spectrally similar
sites. Just as for the dysplastic/malignant category,
we use the slash notation (eg, FM/VT) in the text
that follows to refer to a group that combines sam-
ples from 2 sites.
For algorithm development, it is important to
have a sufficient number of samples in each cate-
gory. In this study, we used the criterion of at least
10 samples per category. Table 3 lists the numbers
of benign and dysplastic/malignant lesions for each
of the 3 pairs. For the FM/VT group, we analyzed
samples from every category (healthy mucosa, le-
sions, benign lesions, and dysplastic/malignant le-
sions). For the BM/SP group, we analyzed samples
from the healthy mucosa, lesion, and benign lesion
categories.
Distinguishing Healthy Mucosa From Lesions.
We first examined the benefit of anatomy-based al- "
gorithms when applied to the distinction of healthy
mucosa samples from lesions. Table 4 lists the
ROC-AUC results for discriminating healthy mu-
cosa (HV data) from visible lesions (patient data).
In each case, the results are shown for all sites com-
bined (9 sites total), nonkeratinized sites (all sites
except the GI and HP), individual sites, and spec-
trally similar sites. Our prior study in HVs clearly
demonstrated that the GI and HP display significant
spectral contrast from most other sites for several
spectroscopy parameters .^ ^ By analyzing nonkerati-
nized sites separately, we eliminate spectral contrast
due to keratin, and can determine whether eliminat-
ing it improves the identification of lesions among
the remaining sites in the group.
The results in Table 4 indicate that excellent dis-
crimination between healthy mucosa and lesions
is possible with spectroscopy (ROC-AUC, 0.81 to
0.97), particularly when the diagnostic algorithms
are developed and applied to individual sites or
spectrally similar sites. The diagnostic performance
of the spectral algorithms was poorest for the group
in which all sites were combined (ROC-AUC, 0.81
to 0.85). The spectroscopy parameters frequently
Group
All sites
Nonkeratinized
LT
FM
BM*
VT
FM/VT
BM/SP*
ROC-AUC -
*No dysplastic
Healthy
Mucosa vs
Lesions
0.83
sites 0.84
0.95
0.94
0.94
0.95
0.97
0.91
Healthy
Mucosa vs
Dysplastic/
Malignant
Lesions
0.85
0.88
0.97
0.95
0.97
Healthy
Mucosa vs
Benign
Lesions
0.81
0.84
0.93
0.96
0.94
0.90
area under receiver operator characteristic curve.
samples.
identified as diagnostic included NADH (340 nm),
cßC, tryptophan (308 nm), Coll427 (340 nm), and
a. The effective vessel radius. Coll (308 nm), and A
and C parameters were not diagnostic.
When lesions were compared to healthy mucosa,
the parameter trends were found to be identical for
all 3 separations: healthy mucosa versus all lesions,
benign lesions, and dysplastic/malignant lesions,
respectively. Lesions were characterized by high-
er B parameter, cHb, a, tryptophan (308 nm), and
NADH (340 nm) and by lower cßC, NADH (308
nm), Coll401 (340 nm), and Coll427 (340 nm). We
compared the parameter trends for lesions relative to
healthy mucosa to the trends for healthy keratinized
sites (GI and HP) relative to healthy nonkeratinized
sites. The latter comparison was used as a marker
for the influence of keratin; however, mucosal fea-
tures specific to the GI and HP may also contribute
to the trends. The trends for both comparisons were
identical for 7 of the 9 spectroscopy parameters em-
ployed in the spectral diagnostic models (data not
shown).
Distinguishing Benign Lesions From Dysplastic/
Malignant Lesions, We next evaluated the benefit
of anatomy-based algorithms for a clinically rel-
evant distinction, the discrimination of benign le-
sions from dysplastic/malignant lesions. Spectral al-
gorithms were developed for the 4 groups with at
least 10 samples in the 2 lesion categories: all sites
combined, nonkeratinized sites, the LT alone, and
the FM/VT group. The Figure shows ROC curves
for all sites combined, the LT alone, and the FM/VT
group. The ROC curve for all sites combined dem-
onstrated the poorest discriminatory power.
Table 5 lists the ROC-AUC values, sensitivities,
and specificities for the discrimination of benign le-
sions from dysplastic/malignant lesions. The high-
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TABLE 6. SIGNIFICANT DIAGNOSTIC PARAMETERS
FOR DISCRIMINATION OF BENIGN LESIONS FROM
DYSPLASTIC/MALIGNANT LESIONS
All sites combined
FM/VT
0.0 0.2 0.8 1.00.4 0.6
1 - Specificity
Receiver operator characteristic curves for discrimina-
tion of benign lesions from dysplastic/malignant lesions
for all sites combined (hatched line), lateral surface of
tongue (LT; thick dashed line), and floor of mouth/ven-
tral surface of tongue (FM/VT; thick solid line).
est ROC-AUC value (0.75) was obtained for the
LT, and once again, the lowest value (0.60) was ob-
tained when all sites were combined. The diagnostic
performance of the FM/VT group was considerably
better than that of all sites combined.
Table 6 lists the spectroscopy parameters that were
combined to yield the performance values shown in
Table 5. The diagnostic parameters were almost en-
tirely different from those used to separate healthy
mucosa from lesions (data not shown). Although
the C parameter was not diagnostic in distinguish-
ing healthy mucosa from lesions, it played a signifi-
cant role in separating benign lesions from dysplas-
tic/malignant lesions. Similarly, Coll401 (340 nm)
had greater significance in separating benign lesions
from dysplastic/malignant lesions than in separating
healthy mucosa from lesions. The cßC continued to
be an important diagnostic parameter. Dysplastic/
malignant lesions were characterized by higher C
parameter and cHb and by lower cßC, Coll401 (340
nm), and Coll427 (340 nm).
DISCUSSION
The oral cavity is complex, in that it consists of
TABLE 5. ROC-AUC, SENSITIVITY, AND SPECIFICITY
VALUES FOR DISCRIMINATION OF BENIGN LESIONS
FROM DYSPLASTIC/MALIGNANT LESIONS
Sensitivity Specificity
(Based on (Based on
Youden Youden
Group ROC-AUC Index) Index)
All sites 0.60 53% 70%
Nonkeratinized sites 0.63 49% 76%
LT 0.75 92% 67%
FM/VT 0.71 94% 60%
Group
All sites
Nonkeratinized sites
LT
FM/VT
BM/SP*
*No dysplastic samples.
Diagnostic Parameters for Benign
Lesions vs Dysplastic/
Malignant Lesions
C parameter, Coll40l (340 nm), cßC
C parameter, Coll401 (340 nm), cßC
cßC,Coll401 (340 nm)
C parameter, Coll427 (340 nm), cHb
A parameter
multiple morphologically distinct anatomic sites,
each of which is characterized by its own spectral
properties. In many clinical studies, only a limited
amount of data can be collected in a practical time
period; therefore, data from all anatomic sites are
combined to maximize the number of samples in
each category. Consequently, differences in the his-
tologie characteristics between the anatomic sites
may confound the detection of spectral contrast re-
lated to the presence of disease. We developed a
strategy to evaluate whether certain pairs of sites
are comparable in their spectral properties so that
one could combine those sites with a high degree of
similarity. This approach was designed to address 2
potential pitfalls: 1) combining dissimilar sites may
broaden parameter distributions and make it more
difficult to detect disease-related spectral contrast
and 2) if the sites being combined have different
spectral properties and samples are unevenly dis-
tributed between the 2 categories being compared,
the likelihood is increased that anatomic spectral
contrast may compete with or contribute to the ap-
parent disease-related contrast. We identified 3 pairs
of spectrally similar sites: 1) BM and SP, 2) FM and
VT, and 3) GI and HP.
Distinguishing Healthy Mucosa From Lesions.
The results of this comparison demonstrated the
significant influence of anatomic spectral contrast
on diagnostic accuracy, as well as a clear benefit
to combining spectrally similar sites. As in other
studies, we obtained excellent results for this com-
parison; however, anatomy-based algorithms were
more accurate (ROC-AUC, 0.90 to 0.97) than were
algorithms developed for all sites combined (ROC-
AUC, 0.81 to 0.85). We tested an alternative ap-
proach for combining multiple sites on the basis of
a morphological criterion, only combining nonkera-
tinized sites together. The performance of the diag-
nostic algorithm for the nonkeratinized group did
not produce ROC-AUC values dramatically higher
than those for all sites combined. The number of le-
sion samples from keratinized sites in our data set
was limited (5 samples total); however, this finding
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is consistent with our previous observation of sig-
niflcant anatomic spectral contrast among nonkera-
tinized sites, and supports the need for a more ef-
fective strategy for determining which sites to com-
bine25
The excellent separations achieved for compari-
sons between healthy mueosa and lesions may be
influenced by hyperkeratosis, ulcération, or other
mucosal changes associated with lesions that are
not directly linked to malignancy. The spectral con-
trast between healthy mueosa and visible lesions is
largely independent of the presence of disease, as
shown by the comparable ROC-AUC values for dis-
criminating healthy mueosa from benign lesions and
healthy mueosa from dysplastic/malignant lesions
(0.81 to 0.96 and 0.85 to 0.97, respectively). The
parallel parameter trends for lesions compared to
healthy mueosa and healthy keratinized sites com-
pared to healthy nonkeratinized sites provide added
support for the hypothesis that keratin, rather than
disease, is a major source of spectral contrast. These
results indicate that clinically healthy mueosa sam-
ples and samples from elinically abnormal mueosa
(lesions) should be treated as distinct entities. The
high values for the diagnostic accuracy reported for
this comparison in previous studies may in fact be
unrealistically high because of the confounding ef-
fects of mucosal changes that are unrelated to dis-
ease.
The parameter trends we observed when compar-
ing lesions to healthy mueosa are consistent with
those of other studies. In distinguishing healthy mu-
eosa from malignant lesions, Amelink et al'^ noted
that malignant lesions exhibited a lower a, an in-
crease in blood content, and an increase in scattering
slope (B parameter). A decrease in scattering ampli-
tude (A parameter) was also observed, which was
not found in our analysis. Müller et al^ also noted in-
creased NADH and decreased collagen fluorescence
for lesions excited at 340 nm. The increase in the B
parameter is most likely due to scattering from kera-
tin present in leukoplakias, as previous work has
shown that this parameter is greatly affected by this
feature.25 Vascular dilation or inflammation in ul-
cerated lesions or erythroplakias may give rise to an
increased cHb. The decreased collagen fluorescence
at 340 nm excitation, which may result from degra-
dation of the extracellular matrix by matrix metal-
loproteinases, has been noted in numerous spectro-
scopic studies."-39-41 The increased NADH at 340
nm excitation may be due to the increased metabolic
activity of abnormal proliferating epithelial cells.
Distinguishing Benign Lesions From Dysplastic/
Malignant Lesions. The results for the distinction
of healthy mueosa from lesions demonstrated the
benefit of anatomy-based algorithms, but this appli-
cation has no real clinical importance. Therefore, we
applied the anatomy-based algorithms to the distinc-
tion of benign lesions from dysplastic/malignant le-
sions. Once again, the best diagnostie performance
was obtained for the individual site (LT), and the
poorest performance for all sites combined (ROC-
AUC, 0.60). The FM/VT group (spectrally similar
sites) also produced more accurate results (ROC-
AUC, 0.71) than did all sites combined. We did not
evaluate the BM/SP group, because it did not meet
the criterion of at least 10 samples in each category.
The ROC-AUC values obtained for the distinc-
tion of benign lesions from dysplastic/malignant
lesions were significantly lower than those for the
distinction of healthy mueosa from lesions. Further-
more, very few parameters were statistically signif-
icant in the diagnostic model for the former com-
parison. Therefore, the diagnostic accuracies report-
ed in studies eomparing healthy mueosa to lesions
may be misleading, because they do not reflect how
spectroscopy performs when applied to clinically
important diagnostic distinctions. The heterogene-
ity of lesions within each category contributes to
the challenge of distinguishing lesion eategories and
can further obscure subtle disease-related changes
in the spectroscopy parameters. Some malignant le-
sions had small foci of invasion in a large area of
relatively normal mueosa, whereas others demon-
strated more diffuse disease. Similarly, the benign
lesions ranged from mildly to highly hyperkeratotic,
with various degrees of hyperplasia and inflamma-
tion. Interindividual variation is another source of
spectral contrast that may affect diagnostic perfor-
mance.
Another approach for combining sites, employed
by some researchers, is to combine healthy mueosa
samples with benign lesions. This can dramatical-
ly increase the number of samples in the negative-
for-dysplasia/malignancy category, because healthy
mueosa samples are readily available. However, this
approach may produce misleading results for 2 rea-
sons. First, we have shown that there is significant
spectral contrast between healthy mueosa and le-
sions even in the absence of disease. Second, our
findings demonstrate a marked difference in spec-
tral contrast between benign lesions and dysplas-
tic/malignant lesions, as compared to healthy mu-
eosa and visible lesions. Therefore, the diagnostic
performance may falsely appear to improve as the
proportion of healthy mueosa samples in the neg-
ative group increases. To test this hypothesis, we
combined 10 LT healthy mueosa samples with the
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henign LT lesions. Whereas an ROC-AUC value of
0.75 was ohtained for distinguishing henign lesions
from dysplastie/malignant lesions, the ROC-AUC
value increased to 0.85 when we used the eomhined
healthy mueosa/henign lesion category (data not
shown). When 50 LT healthy mueosa samples were
eomhined with the same benign samples, the ROC-
AUC value increased further, to 0.91. These results
underscore the importanee of considering how data
are eomhined in order to reliahly evaluate spectral
diagnostic algorithms.
We examined the trends in the spectral parame-
ters used in the diagnostic models with increasing
disease severity. The increase in the C parameter is
eonsistent with increased scattering hy small parti-
cles, as may oeeur with increased epithelial prolifer-
ation. The higher cHh may he the result of vaseular
dilation and inflammation as seen in erythroplakias
or with ulcération (features that are more likely to
be assoeiated with dysplasia/malignaney), where-
as white lesions are less hkely to be dysplastic/ma-
lignant upon biopsy.'* '^'*^ Deereased collagen fluo-
rescenee was observed once again for this distinc-
tion. The reason for the deereased eßC is unknown.
ß-Carotene is an antioxidant and can be metabolized
into vitamin A, which is involved in the differentia-
tion of normal epithelial eells."*^
Application of Spectral Algorithms in Clinical
Practice. The current standard screening method
for oral eaneer — inspection with palpation — en-
ahles inspection of the entire oral eavity. Our prohe
may not he appropriate for this purpose, beeause it
samples only a small area of tissue. However, when
patients with suspicious lesions are referred to an
otolaryngologist, speetroseopy may be useful for
distinguishing benign lesions from dysplastie/ma-
lignant lesions. A study by Waldron and Shafer42
of 3,256 leukoplakias (the most eommonly eneoun-
tered oral lesions) found that 42.9% of biopsies from
FM lesions and 24.2% of biopsies from tongue le-
sions exhihited dysplasia/malignaney. Of the 3,256
eases of leukoplakia, 6.8% and 8.6%, respeetively,
were located at these sites. If we eonsider 1,000 pa-
tients with leukoplakia of the tongue or FM, a to-
tal of 442 FM lesions and 558 tongue lesions would
he expeeted, given the relative frequeney of leuko-
plakia at these 2 sites noted in that study. Of these
patients, 32.5% would he expeeted to show dyspla-
sia/malignaney (42.9% of FM lesions and 24.2% of
tongue lesions). The performance values for the LT
and FM/VT sites are similar, so we use the aver-
age values of 93% and 64% as the sensitivity and
specificity, respeetively, of the spectral diagnostie
test. Based on these values and the aforementioned
prevalenee estimates for diseased lesions, the posi-
tive and negative predietive values for our test are
55% and 95%, respeetively. These results indicate
that our spectral algorithms ean identify the absenee
of dysplasia/malignaney, with few false negatives,
thereby redueing the number of unnecessary biop-
sies. A large prospective study is needed to rigor-
ously confirm these findings.
CONCLUSIONS
The results of this study demonstrate the impor-
tanee of developing anatomy-based algorithms for
disease detection in the oral cavity. Combining mul-
tiple anatomic sites without accounting for anatom-
ie spectral eontrast redueed disease-related eontrast
and resulted in poor diagnostie performanee. Spec-
tral algorithms designed specifically for multiple an-
atomie sites sharing a high degree of spectral simi-
larity considerably improved diagnostie aeeuraeies.
The best diagnostie performanee was achieved when
anatomy-hased algorithms were developed for indi-
vidual sites. The diserimination of healthy mueosa
from lesions yielded excellent results, as in previous
studies, but the findings do not extend to the elini-
eally relevant distinction of henign lesions from dys-
plastie/malignant lesions. However, anatomy-based
algorithms signifieantly improved diagnostie per-
formance for the latter distinetion. Diagnostie aeeu-
raeies for distinguishing healthy mucosa/benign le-
sions from dysplastie/malignant lesions were depen-
dent on the proportion of healthy mueosa samples
and were therefore unreliable, even with the use of
anatomy-hased algorithms. This study demonstrates
a successful approach for developing eommon algo-
rithms for multiple anatomic sites while accounting
for anatomie spectral eontrast.
Developing a spectral diagnostie algorithm for
every anatomie site may not be neeessary to pro-
vide a substantial elinieal benefit. One potential
future direetion is to develop a reliable diagnostie
tool designed speeifieally for sites at high risk for
oral eaneer. To ensure that dysplasia or malignaney
is not missed, biopsies are likely to be taken of le-
sions at these sites; therefore, a tool for identifying
henign lesions eould reduce the numher of unnec-
essary hiopsies. Alternatively, unnecessary biopsies
eould be redueed by developing a tool for sites at
whieh lesions are frequently eneountered but gener-
ally prove benign by histopathology (low likelihood
of disease). Large, prospeetive elinieal studies are
needed to reliably evaluate the efficacy of speetros-
eopy for these applieations. Ultimately, we would
like to detect invisihle disease, partieularly in high-
risk individuals and at surgical margins.
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